ribociclib
novartis
['natalee', 'breast', ' ribo', 'ribociclib']
phase 3 natalee trial results were just presented at #asco23. adjuvant ribociclib + endocrine therapy is well tolerated, decreases risk of recurrence by 25.2%, improves trend in overall survival, compared to endocrine therapy alone in early er+ #breastcancer. 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ